Related Experiment Video
Updated: Jul 4, 2026

Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
Case Report: Fabry disease mimicking coronary artery disease and hypertrophic cardiomyopathy-a 15-year diagnostic
Tielang Liang1, Hongyuan Xu1, Chuang Huang1
1Cardiology Department, The Eighth Affiliated Hospital of Guangxi Medical University, Guangxi, China.
Insights
Fabry disease diagnosis can be delayed due to overlapping symptoms with coronary artery disease and left ventricular hypertrophy. Early identification requires recognizing multi-system involvement and utilizing advanced cardiac imaging and genetic testing.
Area of Science:
- Cardiology
- Genetics
- Rare Diseases
Background:
- Fabry disease is a rare X-linked lysosomal storage disorder.
- Cardiac symptoms often mimic hypertrophic cardiomyopathy or coronary artery disease, delaying diagnosis.
Background:
Fabry disease is a rare X-linked hereditary lysosomal storage disorder. Its cardiac manifestations often overlap with those of hypertrophic cardiomyopathy or coronary artery disease, leading to significant delays in diagnosis.
Case Summary:
A 60-year-old male patient presented with exertional angina pectoris, which had persisted for 15 years. Initially diagnosed with coronary artery disease, he underwent percutaneous coronary intervention. Despite successful revascularization, he subsequently developed progressive left ventricular hypertrophy, heart failure, bilateral hearing loss, dizziness, and white matter lesions in the brain. Cardiac magnetic resonance imaging revealed mid-myocardial striae-like late gadolinium enhancement and left ventricular high voltage on electrocardiography, raising a strong suspicion of Fabry disease. Plasma α-galactosidase A activity was significantly decreased (0.62 μmol/L), and genetic testing identified a hemizygous pathogenic variant in the GLA gene [c.718_719del (p.K240fs)], confirming the diagnosis of Fabry disease. Due to various reasons, enzyme replacement therapy was not initiated, and the patient is currently managed with a heart failure and secondary prevention regimen for coronary artery disease, with stable disease status.
Discussion:
This case highlights the challenges in identifying Fabry disease in patients with coexisting coronary artery disease and left ventricular hypertrophy. It emphasizes the diagnostic value of multi-system involvement and characteristic imaging findings. A diagnostic pathway incorporating clinical warning signs, cardiac magnetic resonance imaging, enzymatic assays, and genetic testing can help reduce diagnostic delays.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Acute Coronary Syndrome III: Diagnostic Studies
Mitral Stenosis II: Clinical features and Diagnostic Tests
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
